Thorne HealthTech

Thorne HealthTech, Inc. is engaged in the provision of a total system for wellness. It utilizes testing and data to create improved product quality and deliver personalized solutions to consumers, health professionals, and professional sports teams. It also helps pharmaceutical and biotechnology companies repurpose existing drugs and compounds, improve existing medications and develop new products. The company was founded by Paul Jacobson in 2010 and is headquartered in New York, NY.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK , May 30, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne") (the "Company") (NASDAQ: THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, announced today that it will participate in TD Cowen's 7th Annual Future of the Consumer Conference in New York City. On Wednesday, June 7, at 10:45 a.m.

Thorne HealthTech to Participate in TD Cowen's 7th Annual Future of the Consumer Conference on June 7

NEW YORK , May 15, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne") (NASDAQ: THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, announced today that it is entering into a research and development partnership agreement with Arome Science, a leader in metabolomics, to develop a next-generation metabolomics test. Arome Science and Thorne will collaborate to develop a commercial metabolomics wellness test.

Thorne HealthTech Enters into Research and Development Partnership with Arome Science to Develop Next-Generation Metabolomics Test

Thorne HealthTech, Inc. (NASDAQ:THRN ) Q1 2023 Earnings Conference Call May 11, 2023 5:30 PM ET Company Participants Thomas Wilson - VP, IR Paul Jacobson - CEO Saloni Varma - CFO Tom McKenna - COO Michelle Crow - CMO Conference Call Participants Sean Dodge - RBC Elizabeth Anderson - Evercore Susan Anderson - Canaccord Steven Mah - TD Cowen Operator Good afternoon. Thank you for attending today's Thorne HealthTech, Inc. First Quarter 2020 Earnings Call.

Thorne HealthTech, Inc. (THRN) Q1 2023 Earnings Call Transcript

Net Sales Growth of 20.7%; Reaffirms Full-Year 2023 Guidance NEW YORK , May 11, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech", "Thorne" or the "Company") (NASDAQ: THRN), a leader in delivering personalized, innovative solutions that empower individuals to live healthier, longer lives, today announced its financial results for the first quarter ended March 31, 2023. First Quarter Highlights: Net sales grew 20.7% year-over-year to $65.2 million, with direct-to-consumer ("DTC") sales growth of 41.0% Gross profit grew 16.3% year-over-year to $34.3 million; gross profit as a % of net sales decreased year-over-year to 52.5% Net loss attributable to Thorne HealthTech, Inc. of $(0.4) million; adjusted EBITDA1 of $6.1 million Diluted earnings per share ("EPS") of $(0.01); adjusted diluted EPS1 of $0.06 Named to Fast Company's annual list of the most innovative companies in wellness for 2023 "We delivered strong sales performance across the business during the first quarter," said Paul Jacobson, Thorne HealthTech's chairman and CEO.

Thorne HealthTech Reports First Quarter 2023 Results

NEW YORK , May 3, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne") (the "Company") (NASDAQ: THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, announced today that it will participate in the 2023 RBC Capital Markets Global Healthcare Conference in New York City. On Tuesday, May 16 at 3:35 p.m.

Thorne HealthTech to Participate in the 2023 RBC Capital Markets Global Healthcare Conference on May 16

NEW YORK , May 3, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne") (NASDAQ: THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, announced today that its OneDraw® Blood Collection Device has been selected as the Best Overall Medical Device Product in the eighth annual MedTech Breakthrough Awards program. MedTech Breakthrough is an independent market intelligence organization that recognizes the "breakthrough" companies, individuals, platforms, and products in today's health, fitness, and medical technology industries.

Thorne HealthTech Wins 2023 MedTech Breakthrough Award for Best Overall Medical Device Product for Thorne's OneDraw® Blood Collection Device

NEW YORK , May 1, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. (NASDAQ: THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, will release its first quarter 2023 financial results after market close on Thurs, May 11, 2023. The company will host a conference call to discuss its results on Thurs, May 11, 2023, at 5:30 p.m.

Thorne HealthTech Schedules First Quarter 2023 Earnings Release and Conference Call

Thorne HealthTech, Inc. (NASDAQ:THRN ) Q4 2022 Earnings Conference Call March 31, 2023 8:00 AM ET Company Participants Thomas Wilson – Vice President-Investor Relations Paul Jacobson – Chief Executive Officer Michelle Crow – Chief Medical Officer Tom McKenna – Chief Operating Officer Conference Call Participants Elizabeth Anderson – Evercore Susan Anderson – Canaccord Genuity Steven Mah – Cowen Operator Hello everyone, and welcome to the Thorne HealthTech Fourth Quarter 2022 Earnings Call. My name is Charlie and I'll be coordinating the call today.

Thorne HealthTech, Inc. (THRN) Q4 2022 Earnings Call Transcript

Net Sales Growth of 24.1% and Adj. EBITDA1 growth of 19.1% for Full-Year 2022; Provides Full-Year 2023 Guidance NEW YORK , March 30, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech", "Thorne" or the "Company") (NASDAQ: THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, today announced its financial results for the fourth quarter and full-year ended December 31, 2022.

Thorne HealthTech Reports Fourth Quarter and Full-Year 2022 Results

NEW YORK , March 29, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. (NASDAQ: THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, will release its fourth quarter and full-year 2022 financial results after market close on Thurs, Mar. 30, 2023. The company will host a conference call to discuss its results on Fri, Mar. 31, 2023, at 8 a.m.

Thorne HealthTech Announces Fourth Quarter and Full-Year 2022 Earnings Release Date and Conference Call

NEW YORK , March 13, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne" or "Thorne HealthTech") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellness, today announced that it has appointed Saloni Varma as Chief Financial Officer (CFO). As CFO, Varma will lead all aspects of the company's Accounting and Finance functions including budgeting planning and analysis, accounting, SEC reporting, tax, treasury, and investor relations.

Thorne HealthTech Appoints Saloni Varma as New Chief Financial Officer

Acquisition of PreCon strengthens brain health portfolio and provides access to world-class scientific advisory board NEW YORK , Feb. 3, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne" or "Thorne HealthTech") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellness, today announced it has acquired all of the outstanding stock of PreCon Health, Inc. ("PreCon"), a company focused on scientific discovery, innovation, and advancing safe and effective products that support healthy brain function. The acquisition was completed on January 31, 2023, for an aggregate purchase price of $5.0 million.

THORNE HEALTHTECH ACQUIRES PRECON HEALTH

Thorne HealthTech continues to face lower revenue growth due to macro uncertainty. Management prefers to temporarily sacrifice the gross margin, but increase brand awareness.

Thorne HealthTech: Strong Fundamental Potential But Cost Pressure Remains

NEW YORK , Jan. 9, 2023 /PRNewswire/ -- On January 3, 2023, the U.S. Circuit Court of Appeals for the Federal Circuit in Washington, D.C., issued a final ruling rendering the previously issued U.S. Patent No.

U.S. Appeals Court Issues Final Ruling That Upholds Thorne HealthTech Inc.'s Prior Challenge of Nicotinamide Riboside Intellectual Property Claim

NEW YORK , Nov. 16, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or "the Company") (NASDAQ: THRN), a leader in developing personalized, innovative solutions to live healthier lives longer, today announced it will participate in a fireside chat and also meet with investors at the upcoming Evercore ISI HEALTHCONx Conference. A live webcast and replay of the fireside chat will be available on Wednesday, November 30, at 1:50 p.m.

Thorne HealthTech to Participate in Evercore ISI HEALTHCONx Conference

Thorne HealthTech, Inc. (NASDAQ:THRN ) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Thomas Wilson - Vice President, Investor Relations Paul Jacobson - Chief Executive Officer Bryan Conley - Chief Financial Officer Michelle Crow - Chief Marketing Officer Conference Call Participants Elizabeth Anderson - Evercore Sean Dodge - RBC Capital Markets Max Rakhlenko - Cowen and Co. Operator Welcome to the Thorne HealthTech Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.

Thorne HealthTech, Inc. (THRN) Q3 2022 Earnings Call Transcript

Updates Full-Year 2022 Guidance NEW YORK , Nov. 9, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech", "Thorne" or the "Company") (NASDAQ: THRN), a leader in developing personalized, innovative solutions that empower individuals to live healthier, longer lives, today announced its financial results for the third quarter ended September 30, 2022. Third Quarter Highlights: Net sales grew 21.7% year-over-year to $58.4 million, with direct-to-consumer ("DTC") sales growth of 47.2% Gross profit grew 10.3% year-over-year to $28.2 million; gross margin decreased 500 basis points year-over-year to 48.2% Net income attributable to common stockholders grew to $3.7 million; adjusted EBITDA grew to $8.3 million Diluted earnings per share ("EPS") of $0.07; adjusted diluted EPS of $0.12 "People trust Thorne to support their daily wellness journeys because of the personalization we offer, the science behind our portfolio of solutions including our health tests and supplements, and our unmatched quality standards," said Paul Jacobson, Thorne HealthTech's chairman and CEO.

Thorne HealthTech Reports Third Quarter 2022 Results

NEW YORK , Oct. 25, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellness, announced today that it is collaborating with GenTegra, an innovator and leader of complete biological sample protection, to utilize GenTegra's patented Active Chemical Protection™ technology and Thorne's OneDraw™ collection device to develop a whole blood DNA collection cartridge and a complete stabilization and extraction kit. The collaboration paves the way for Thorne and GenTegra to introduce a product that will be inclusive of Thorne's OneDraw DNA cartridges and GenTegra's GenSolve technology for highly efficient DNA extraction.

THORNE HEALTHTECH AND GENTEGRA COLLABORATE TO DEVELOP A NEXT-GENERATION WHOLE BLOOD DNA COLLECTION AND EXTRACTION KIT

NEW YORK , Oct. 18, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. (NASDAQ:  THRN ), a leader in developing innovative solutions for a personalized approach to health and wellness, will release its third quarter 2022 financial results after market close on Wednesday, Nov. 09, 2022. The company will host a conference call to discuss its results on Thursday, Nov. 10, 2022, at 8 a.m.

Thorne HealthTech Announces Third Quarter 2022 Earnings Release Date and Conference Call

Multi-year collaboration to introduce top athletes and casual gamers alike to science-driven products that support enhanced performance and a healthy lifestyle NEW YORK , Sept. 29, 2022 /PRNewswire/ -- Thorne HealthTech ("Thorne") (NASDAQ: THRN), the leader in developing innovative solutions for a personalized approach to health and wellness and Team Liquid, a leading worldwide professional esports organization, today announced that Thorne is now the official Health and Wellness Partner of Team Liquid.

THORNE AND TEAM LIQUID ANNOUNCE PARTNERSHIP BRINGING INNOVATIVE HEALTH AND WELLNESS SOLUTIONS TO THE ESPORTS COMMUNITY

Thorne HealthTech went public in September 2021, raising approximately $70 million in a U.S. IPO. The company designs and sells wellness and nutraceutical products worldwide.

Thorne HealthTech Grows But Faces Macro Headwinds

NEW YORK , Aug. 23, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellness and majority owner of Drawbridge Health announced today that its OneDraw™ Blood Collection Device has been certified in Japan as a medical device, having been cleared by the Pharmaceutical and Medical Devices Agency (PMDA). "This is a major victory for the OneDraw device because the PMDA has notoriously stringent qualifications to clear a device," said Paul Jacobson, CEO of Thorne HealthTech.

Thorne HealthTech's OneDraw™ Blood Collection Device Receives PMDA Certification in Japan

Thorne HealthTech, Inc. (NASDAQ:THRN ) Q2 2022 Earnings Conference Call August 10, 2022 8:00 AM ET Company Participants Thomas Wilson - Vice President, Investor Relations Paul Jacobson - Chief Executive Officer Bryan Conley - Chief Financial Officer Michelle Crow - Chief Marketing Officer Conference Call Participants Sean Dodge - RBC Capital Markets Oliver Chen - Cowen and Company Operator Hello and welcome to today's Thorne HealthTech Second Quarter 2022 Earnings Call. My name is Bailey, and I will be your moderator for today's call.

Thorne HealthTech, Inc. (THRN) CEO Paul Jacobson on Q2 2022 Results - Earnings Call Transcript

Revises Full-Year 2022 Guidance NEW YORK , Aug. 9, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech", "Thorne" or the "Company") (NASDAQ: THRN), a leader in developing personalized, innovative solutions to help people live healthier, longer lives, today announced its financial results for the second quarter ended June 30, 2022. Second Quarter Highlights: Net sales grew 30.7% year-over-year to $56.1 million, with direct-to-consumer (DTC) sales growth of 69.6% Gross profit grew 37.0% year-over-year to $31.4 million; gross margin increased 260 basis points year over year to 55.9% Net loss attributable to common stockholders of $5.6 million; adjusted EBITDA loss of $1.4 million Diluted loss per share of $0.11; adjusted diluted loss per share of $0.05 Revised full-year 2022 guidance for projected net sales of $235 million to $242 million; adjusted EBITDA of $28 million to $32 million; and adjusted earnings per share (EPS) of $0.36 to $0.39; previously issued guidance for projected gross margin of 53% to 55% reaffirmed "I am pleased to report record quarterly net sales, which grew 30.7% over the second quarter of last year, with continued gross margin expansion to 55.9% for the quarter," said Paul Jacobson, Thorne HealthTech's chairman and CEO.

Thorne HealthTech Reports Second Quarter 2022 Results

NEW YORK , Aug. 4, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellness, today announced a two-year continuation of the collaboration with AstraZeneca, a leading biopharmaceuticals company. The extended collaboration will see the internalization of Thorne's disease discovery platform into AZ for further evaluation and to gain insight into additional uses for AZ molecules.

News for Thorne HealthTech Stock (THRN)